Zobrazeno 31 - 40
of 1 203
pro vyhledávání: ''
Autor:
Rosenberg, Lynn, Boggs, Deborah, Bethea, Traci, Wise, Lauren, Adams-Campbell, Lucile, Palmer, Julie
Publikováno v:
Cancer Causes & Control; Dec2013, Vol. 24 Issue 12, p2207-2215, 9p, 5 Charts
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Autor:
Nelofar Nargis, Gunjan Mandal, Samir Jana, Thomas A. Hughes, Soumya Chatterjee, Annesha Chatterjee, Laura M. Wastall, Himansu Roy, Arindam Bhattacharyya
Publikováno v:
British Journal of Cancer
BACKGROUND: Cancer-associated fibroblasts (CAFs) are known to impact on tumour behaviour, but the mechanisms controlling this are poorly understood. METHODS: Breast normal fibroblasts (NFs) or CAFs were isolated from cancers by laser microdissection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957384df57b4414e3eef66fa38c6c18b
https://eprints.whiterose.ac.uk/149993/8/s41416-019-0566-7.pdf
https://eprints.whiterose.ac.uk/149993/8/s41416-019-0566-7.pdf
Autor:
Hisashi Motomura, Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Shuhei Tomita, Koji Takada, Masahiko Ohsawa, Katsuyuki Takahashi, Kosei Hirakawa, Masaichi Ohira, Tsutomu Takashima, Takaharu Hatano
Publikováno v:
British Journal of Cancer
Background Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, li
Publikováno v:
Breast Cancer Research & Treatment; Feb2013, Vol. 138 Issue 1, p291-301, 11p
Autor:
Cianfrocca, Mary
Publikováno v:
Current Breast Cancer Reports; Mar2012, Vol. 4 Issue 1, p83-88, 6p
Autor:
Meijer-van Gelder, Marion, Look, Maxime, Bolt-de Vries, Joan, Peters, Harry, Klijn, Jan, Foekens, John
Publikováno v:
Breast Cancer Research & Treatment; Aug2001, Vol. 68 Issue 3, p249-260, 12p
Autor:
Marta Román, Margarita Posso, Javier Louro, Xavier Castells, Michele Hilton Boon, Laia Domingo, Maria Sala
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
British Journal of Cancer
Universitat Autònoma de Barcelona
British Journal of Cancer
Background: \ud Individualised breast cancer risk prediction models may be key for planning risk-based screening approaches. Our aim was to conduct a systematic review and quality assessment of these models addressed to women in the general populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69319a82ea0352c185176ef68f88ddc8
https://eprints.gla.ac.uk/187692/1/187692.pdf
https://eprints.gla.ac.uk/187692/1/187692.pdf
Autor:
Michael S. Toss, Emad A. Rakha, Chitra Joseph, Padmashree C.G. Rida, Andrew R. Green, Ian O. Ellis, Nigel P. Mongan, Mohammed A. Aleskandarany, Ibrahim Alshankyty, Mansour Alsaleem, Sasagu Kurozumi, Angela Ogden, Ritu Aneja
E-cadherin is a tumor suppressor gene in invasive lobular breast cancer. However, a proportion of high-grade ductal carcinoma shows reduced/loss of E-cadherin. In this study, we assessed the underlying mechanisms and molecular implications of E-cadhe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4fd096ae4d5a4d6360edf9b34a9f20
https://clok.uclan.ac.uk/34530/1/34530.pdf
https://clok.uclan.ac.uk/34530/1/34530.pdf
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf